D2G Oncology, Inc. — Form D/A
D2G Oncology, Inc. of MOUNTAIN VIEW, CA, a company, filed a Form D amendment with the SEC on 2020-04-27. The offering totals $8.7M, of which $8.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-04-27
- Form: D/A
- Accession: 0001804747-20-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.7M
- Amount sold: $8.7M
- Investors: 12
- Date of first sale: 2020-02-12
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-361569
Issuer
- Name: D2G Oncology, Inc.
- CIK: 0001804747
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 297 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
- Phone: 000-000-0000
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Kathleen D LaPorte | Director | Mountain View, CA |
| Jonathan MacQuitty | Director | Menlo Park, CA |
| Dmitri Petrov | Director | Mountain View, CA |
| Monte Winslow | Director | Mountain View, CA |
| Jonathan MacQuitty | Executive Officer | Menlo Park, CA |
| Kathy LaPorte | Director | Mountain View, CA |
Other filings by this issuer (1)
More